Director of Cerebral Organoid Drug Screening Core and Manager of the Molecular Neuro-Oncology Laboratory at the Meyer Cancer Center, Weill Cornell College of Medicine
The individual appointed to this newly established leadership position will, in collaboration with the program’s principal investigator, help organize and supervise the operations of the Molecular Neuro-Oncology Laboratory and the new Cerebral Organoid Drug Screening Core at the Meyer Cancer Center, Weill Cornell College of Medicine. The responsibilities of this position include directing the cerebral organoid/glioma drug screening core toward CLIA-certification and prospective, patient-specific drug screening clinical trials, as well as supervising and supporting the work of various members of the laboratory and core including post-doctorate trainees, students, scientific and technical staff. The position entails a broad range of important responsibilities including providing intellectual contributions to project design, data analysis, grant applications, and manuscript writing. Responsibilities also include the evaluation, implementation and optimization of existing and emerging molecular and cellular protocols, technologies and applications in order to assure the smooth technical cutting-edge operation of the program. Finally, in addition to helping ensure the financial operation of the laboratory and core, the Core Director/Lab Manager will work closely with the principal investigator of the program to stimulate a highly innovative, exciting and productive scientific environment for all members of the laboratory and core.
A few of our publications that represent the kind of research we do include: Cancer Cell. 9: 287-300, 2006; Cancer Research. 66(19): 9428-36, 2006; Cancer Cell. 9(5):391-403, 2006; Cancer Res. 6(1):21-30, 2008; Cancer Cell 13(1):69-80, 2008; Cell Stem Cell. 4(5): 440-52, 2009.; Cancer Research, 2009; 69(4): 1596-1603, 2009; Cancer Cell.15(4): 247-9, 2009; Cell Stem Cell 4(6): 466-7, 2009; Bioinformatics. 26:1792-3, 2010; Cancer Cell. 18:543-5, 2010; Nature Reviews Neurol 7:439-50, 2011; PLoS One 6:e14681, 2011, Cancer Cell 20:695-7, 2011; J. Natl. Cancer Instit. 103:1162-78, 2011; Cancer Cell 21; 710, 2012; PLOS One 7:e51407, 2012, Cell Reports 6:313, 2014; PLoS One. 2014 Nov 3;9(11):e111783. doi: 10.1371; Cancer Inform. 2014 Oct 15;13(Suppl 3):33-44. doi: 10.4137; Pharmacogenomics J. 2014 Dec 2. doi: 10.1038/tpj.2014.61.
The laboratory and core involves all aspects of translational science and precision medicine while exploring basic mechanistic studies of tumorigenesis using a combination of genetic, molecular and computational biology approaches.
Please email a letter of interest, curriculum vitae and list of three references to Howard A. Fine, M.D. at: email@example.com.